IMMUNE RESPONSE WKN765803 wird heute noch richtig abgehen - 500 Beiträge pro Seite
eröffnet am 04.08.06 11:22:32 von
neuester Beitrag 06.08.06 13:13:01 von
neuester Beitrag 06.08.06 13:13:01 von
Beiträge: 12
ID: 1.075.043
ID: 1.075.043
Aufrufe heute: 0
Gesamt: 2.478
Gesamt: 2.478
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 245 | |
| gestern 19:02 | 80 | |
| gestern 22:58 | 74 | |
| gestern 11:56 | 55 | |
| gestern 23:36 | 43 | |
| vor 1 Stunde | 42 | |
| gestern 21:36 | 37 | |
| gestern 23:08 | 34 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.503,00 | +0,34 | 294 | |||
| 2. | 2. | 174,09 | -2,09 | 109 | |||
| 3. | 3. | 10,230 | +447,06 | 107 | |||
| 4. | 4. | 0,1935 | +2,38 | 77 | |||
| 5. | 7. | 0,9600 | -14,29 | 70 | |||
| 6. | 6. | 1,1100 | -3,48 | 60 | |||
| 7. | 5. | 4,1725 | -5,17 | 57 | |||
| 8. | 8. | 5,9840 | -1,55 | 48 |
Feedback
Hallo
Hat hier jemand eine Ahnung warum der Umsatz seit gestern immer stärker wird?
Hab mir gestern welche zu 0,019 zugelegt.
Kommen da noch News?
Danke für die Antworten
Hat hier jemand eine Ahnung warum der Umsatz seit gestern immer stärker wird?
Hab mir gestern welche zu 0,019 zugelegt.
Kommen da noch News?
Danke für die Antworten
Top oder Flop
Wer Spielgeld riskieren will, der sollte sich die Aktie von Immune Response ansehen.
Die Experten von Global Biotech Investing empfehlen sehr risikobereiten und erfahrenen Anlegern die Aktie von Immune Response (WKN 765803) streng limitiert zum Kauf. Die Analysten von IncreMental Advantage hätten vergangene Woche eine Kaufempfehlung ausgesprochen und auf eine massive Unterbewertung der Titel hingewiesen. Der „faire Wert“ der Aktie wurde dabei mit 0,08 bis 0,09 US-Dollar angegeben. Wenn das Unternehmen in den kommenden Monaten Erfolge in den klinischen Phase-II-Tests für das Multiple-Sklerose-Mittel „NeuroVax“ und das HIV/AIDS-Mittel „IR103“ melden kann, dann müsste Immune Response tatsächlich vollkommen neu bewertet werden.
Behandelte Wertpapiere
IMMUNE RESPONSE DL-,0025 (US45252T2050; 765803; IMM1)
Quelle: Der Aktionär ( siehe aktuelle HP)
Wer Spielgeld riskieren will, der sollte sich die Aktie von Immune Response ansehen.
Die Experten von Global Biotech Investing empfehlen sehr risikobereiten und erfahrenen Anlegern die Aktie von Immune Response (WKN 765803) streng limitiert zum Kauf. Die Analysten von IncreMental Advantage hätten vergangene Woche eine Kaufempfehlung ausgesprochen und auf eine massive Unterbewertung der Titel hingewiesen. Der „faire Wert“ der Aktie wurde dabei mit 0,08 bis 0,09 US-Dollar angegeben. Wenn das Unternehmen in den kommenden Monaten Erfolge in den klinischen Phase-II-Tests für das Multiple-Sklerose-Mittel „NeuroVax“ und das HIV/AIDS-Mittel „IR103“ melden kann, dann müsste Immune Response tatsächlich vollkommen neu bewertet werden.
Behandelte Wertpapiere
IMMUNE RESPONSE DL-,0025 (US45252T2050; 765803; IMM1)
Quelle: Der Aktionär ( siehe aktuelle HP)
Antwort auf Beitrag Nr.: 23.314.584 von mister55 am 04.08.06 11:22:32The Immune Response Corporation Receives Approval for Expansion of Phase II Trial in France for Investigative HIV Immunotherapy IR103
The Immune Response Corporation (OTCBB:IMNR ) announced today the receipt of approvals to expand its Phase II IR103 study in drug-naive HIV patients to include clinical sites in France. The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines. Ultimately, more than 200 drug-naive patients will be enrolled in two parallel clinical studies being conducted in France and Italy, Canada and the UK.
"We are very pleased to have obtained regulatory approval to expand our IR103 study into France," said Georgia Theofan, Ph.D., Vice President of Clinical Development of The Immune Response Corporation. "The enrollment of additional patients in Europe will allow us to generate important data on IR103´s role in stabilizing CD4+ cell counts in HIV drug-naive patients."
The study, which includes a rollover patient population from a previous clinical study of the Company´s first generation immunotherapy, REMUNE(R), is designed to assess the safety and ability of various doses of IR103 to induce HIV-specific immunity. The trial will also measure changes in CD4+ counts, a critical marker of HIV disease progression that is used, along with viral load, to determine when a patient should begin antiretroviral therapy. The Company believes an immune-based therapy that stabilizes CD4+ counts could be used to delay initiation of antiretroviral therapy and serve as an important advance in the treatment of HIV. A total of 31 returning and 54 new patients have been enrolled in Italy in the first stage of the study, and enrollment of additional Italian patients in the second stage, in which the French sites will also participate, is already in progress.
For more information about enrolling in this trial please contact The Immune Response Corporation at 760-431-7080 in the United States.
About IR103
More than 25 million people have died since human immunodeficiency virus (HIV) was first recognized in 1981 (source: UNAIDS, December 2005), and the new infection rate continues to grow at an alarming rate. Despite medical advances, the worldwide pandemic continues to claim more than 3.1 million lives each year (source: UNAIDS, December 2005). Additional safe and effective treatments are desperately needed.
IR103 is a second-generation HIV immunotherapy based on the Company´s patented, whole-inactivated virus technology, which was co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company´s first generation HIV product candidate. Preclinical research and recent clinical data show that IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. This product differs from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual´s immune system to fight the virus.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical Company focused on developing products to treat autoimmune and infectious diseases. The Company´s lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company´s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of multiple sclerosis (MS). NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn´s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company´s patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company´s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation´s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
The Immune Response Corporation (OTCBB:IMNR ) announced today the receipt of approvals to expand its Phase II IR103 study in drug-naive HIV patients to include clinical sites in France. The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines. Ultimately, more than 200 drug-naive patients will be enrolled in two parallel clinical studies being conducted in France and Italy, Canada and the UK.
"We are very pleased to have obtained regulatory approval to expand our IR103 study into France," said Georgia Theofan, Ph.D., Vice President of Clinical Development of The Immune Response Corporation. "The enrollment of additional patients in Europe will allow us to generate important data on IR103´s role in stabilizing CD4+ cell counts in HIV drug-naive patients."
The study, which includes a rollover patient population from a previous clinical study of the Company´s first generation immunotherapy, REMUNE(R), is designed to assess the safety and ability of various doses of IR103 to induce HIV-specific immunity. The trial will also measure changes in CD4+ counts, a critical marker of HIV disease progression that is used, along with viral load, to determine when a patient should begin antiretroviral therapy. The Company believes an immune-based therapy that stabilizes CD4+ counts could be used to delay initiation of antiretroviral therapy and serve as an important advance in the treatment of HIV. A total of 31 returning and 54 new patients have been enrolled in Italy in the first stage of the study, and enrollment of additional Italian patients in the second stage, in which the French sites will also participate, is already in progress.
For more information about enrolling in this trial please contact The Immune Response Corporation at 760-431-7080 in the United States.
About IR103
More than 25 million people have died since human immunodeficiency virus (HIV) was first recognized in 1981 (source: UNAIDS, December 2005), and the new infection rate continues to grow at an alarming rate. Despite medical advances, the worldwide pandemic continues to claim more than 3.1 million lives each year (source: UNAIDS, December 2005). Additional safe and effective treatments are desperately needed.
IR103 is a second-generation HIV immunotherapy based on the Company´s patented, whole-inactivated virus technology, which was co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company´s first generation HIV product candidate. Preclinical research and recent clinical data show that IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. This product differs from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual´s immune system to fight the virus.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical Company focused on developing products to treat autoimmune and infectious diseases. The Company´s lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company´s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of multiple sclerosis (MS). NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn´s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company´s patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company´s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation´s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
danke für die news,
nicht schlecht nicht schlecht, könnte heute wirklich noch ne rakete werden.
nicht schlecht nicht schlecht, könnte heute wirklich noch ne rakete werden.
Antwort auf Beitrag Nr.: 23.314.852 von mister55 am 04.08.06 11:41:38Mal gucken was die AMIS heute so machen. Leider sind die ja am Freitag nicht so aktiv.......
Trading Spotlight
Die aktie wird heute in USA fallen ich rechne mit SK 0,022
aber ist nur meine Meinung
aber ist nur meine Meinung
ja denke ich auch mal des es auf die amis ankommen wird, wie es heute weitergeht.
aber das volumen heute ist schon nicht schlecht
aber das volumen heute ist schon nicht schlecht
Antwort auf Beitrag Nr.: 23.315.751 von mister55 am 04.08.06 12:46:09Wäre schon wichtig wenn wir heute in Deutschland so zwischen 3-5 Mio. Aktien handeln............
Antwort auf Beitrag Nr.: 23.314.778 von URANI am 04.08.06 11:37:32du bist ja gut drauf, die nachricht ist vom 1.8. und nix passiert 
Antwort auf Beitrag Nr.: 23.317.485 von specialoffer am 04.08.06 14:53:43Ach ja ist ja nichts passiert! Bist echt ein Experte.....
Haste schon mnal auf das heutige VOLUMEN geachtet
Haste schon mnal auf das heutige VOLUMEN geachtet
Antwort auf Beitrag Nr.: 23.321.962 von URANI am 04.08.06 19:46:17USA 35 Mio.
Deutschland: 4,5 Mio.
und das um viertel vor Acht.........
Deutschland: 4,5 Mio.
und das um viertel vor Acht.........
Außer Volumen nichts gewesen?!?!?!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 294 | ||
| 109 | ||
| 107 | ||
| 77 | ||
| 70 | ||
| 60 | ||
| 57 | ||
| 48 | ||
| 45 | ||
| 44 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 25 | ||
| 22 | ||
| 21 | ||
| 20 | ||
| 18 | ||
| 18 |
